Abstract
Although their specific mechanisms of action are incompletely understood, beta blockers are most likely lower blood pressure and provide target organ protection by several different mechanisms, including inhibition of renin-angiotensine system by decreasing renin release by the jugstaglomerular cells of the kidney, central inhibition of sympathetic nervous system outflow and slowing of heart rate with a decrease in cardiac output. These agents are widely recommended as important parts of antihypertensive regimens and as well as preferred therapies for patients at high risks of coronary heart disease, and including those with angina pectoris, myocardial infarction or heart failure. The third generation beta blockers are distinguished from the earlier class of beta blockers by their vasodilating activity. Labetalol, carvedilol and bucindolol appear to provide a vasodilation primarily through their blockade of alpha-1 rerceptors. Nebivolol is a lipophilic beta reseptor blocker of third generation with distinct beta-1 with selective and vasodilating properties. A number of experimental and human pharmological studies suggest that the vasodilatation is triggered via increasing vascular NO bioavailabilty which is a consequence of stimulation of NO release and antioxidant properties of this compound. The pharmocological profile is characterised by the significant antihypertensive effect as well as lowering of cardiac pre and after load. Nebivolol is well tolerated and does not appear to significantly influence glucose or plasma lipid metabolism. It is devoid of intrinsic sympathomimetic activity (ISA). This article will review patents, novel composition, pharmacology, haemodynamics, antihypertensive efficiency, metabolic effect and tolerability of nebivolol.
Keywords:Nebivolol,endothelium,NO,vasodilation,oxidative stress,Raynaud's syndrome,heart failure,renal failure,stroke,platelet aggregation
Recent Patents on Cardiovascular Drug Discovery
Title: Nebivolol: More Than a Highly Selective Beta Blocker
Volume: 2Issue: 2
Author(s): Yesari Karter
Affiliation:
Keywords:Nebivolol,endothelium,NO,vasodilation,oxidative stress,Raynaud's syndrome,heart failure,renal failure,stroke,platelet aggregation
Abstract: Although their specific mechanisms of action are incompletely understood, beta blockers are most likely lower blood pressure and provide target organ protection by several different mechanisms, including inhibition of renin-angiotensine system by decreasing renin release by the jugstaglomerular cells of the kidney, central inhibition of sympathetic nervous system outflow and slowing of heart rate with a decrease in cardiac output. These agents are widely recommended as important parts of antihypertensive regimens and as well as preferred therapies for patients at high risks of coronary heart disease, and including those with angina pectoris, myocardial infarction or heart failure. The third generation beta blockers are distinguished from the earlier class of beta blockers by their vasodilating activity. Labetalol, carvedilol and bucindolol appear to provide a vasodilation primarily through their blockade of alpha-1 rerceptors. Nebivolol is a lipophilic beta reseptor blocker of third generation with distinct beta-1 with selective and vasodilating properties. A number of experimental and human pharmological studies suggest that the vasodilatation is triggered via increasing vascular NO bioavailabilty which is a consequence of stimulation of NO release and antioxidant properties of this compound. The pharmocological profile is characterised by the significant antihypertensive effect as well as lowering of cardiac pre and after load. Nebivolol is well tolerated and does not appear to significantly influence glucose or plasma lipid metabolism. It is devoid of intrinsic sympathomimetic activity (ISA). This article will review patents, novel composition, pharmacology, haemodynamics, antihypertensive efficiency, metabolic effect and tolerability of nebivolol.
Export Options
About this article
Cite this article as:
Yesari Karter , Nebivolol: More Than a Highly Selective Beta Blocker, Recent Patents on Cardiovascular Drug Discovery 2007; 2 (2) .https://dx.doi.org/10.2174/157489007780832588
| DOI https://dx.doi.org/10.2174/157489007780832588 | Print ISSN 2212-3962 |
| Publisher Name Bentham Science Publisher | Online ISSN 1574-8901 |
Related Journals
Current Radiopharmaceuticals
5Related Articles
- Anti-Inflammatory Drugs and Statins for Arterial Stiffness Reduction
Current Pharmaceutical DesignAir Pollution and Lung Cancer
Current Respiratory Medicine Reviews Mitochondrial-Targeted Antioxidants and Oxidative Stress: A Proteomic Prospective Study
Current Pharmaceutical DesignSynthesis and Cytotoxic Activities of Difluoro-Dimethoxy Chalcones
Anti-Cancer Agents in Medicinal ChemistryPathophysiology of Atherosclerotic Plaque Development
Cardiovascular & Hematological Agents in Medicinal Chemistry Genetic Variation of Human Adrenergic Receptors: From Molecular and Functional Properties to Clinical and Pharmacogenetic Implications
Current Topics in Medicinal ChemistryFGF23 Actions in CKD-MBD and other Organs During CKD
Current Medicinal Chemistry Identification of Disease-Relevant Genes for Molecularly-Targeted Drug Discovery
Current Cancer Drug TargetsIs Time to Change to Halogenated Drugs in Cardiac Surgery, What do we have to do with Propofol?
Current Pharmaceutical DesignThe Histone Deacetylase SIRT6: At the Crossroads Between Epigenetics, Metabolism and Disease
Current Topics in Medicinal Chemistry Sleep Disturbances in Cystic Fibrosis
Current Respiratory Medicine ReviewsCell-Penetrating Peptides as a Potential Drug Delivery System for Effective Treatment of Diabetes
Current Pharmaceutical Design Recent Developments on Coronary Microvasculopathy after Heart Transplantation:A New Target in the Therapy of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology Direct Renin Inhibition: Promising Treatment in Renoprotection?
Recent Patents on Cardiovascular Drug DiscoveryXanthine Oxidase Inhibitor Febuxostat as a Novel Agent Postulated to Act Against Vascular Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Effects of Imidazolic Agonism on Blood Pressure, Sympathetic Activity, Left Ventricular Hypertrophy and Insulin Resistance
Current Hypertension Reviews The Application of X-ray, NMR, and Molecular Modeling in the Design of MMP Inhibitors
Current Topics in Medicinal ChemistryRoles of Cardiovascular Risk Factors in Endothelial Nitric Oxide Synthase Regulation: An Update
Current Pharmaceutical DesignComprehensive Approach to Sarcopenia Treatment
Current Clinical Pharmacology Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy
Current Pharmaceutical Design
[8]ページ先頭